Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Launched by BOSTON SCIENTIFIC CORPORATION · Feb 24, 2014
Trial Information
Current as of June 20, 2025
Recruiting
Keywords
ClinConnect Summary
The Vercise DBS Registry is a clinical trial that aims to gather information about how well the Vercise Deep Brain Stimulation (DBS) System works for treating Parkinson's disease. This study will look at patients from around the world to understand the outcomes of using this system. It will also evaluate specific tools that help doctors program the device, including Image Guided Programming (IGP) and a 3D feature called DBS Illumina.
To participate in this trial, individuals must be at least 18 years old and meet certain medical guidelines for using the Vercise system. However, those with significant cognitive or mental health issues may not be eligible. If accepted into the study, participants can expect to be part of an important effort to improve treatment options for Parkinson's disease through deep brain stimulation, which involves implanting a device that sends electrical signals to the brain to help control symptoms. The trial is currently looking for participants, and everyone, regardless of gender, can join.
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • Meets criteria established in locally applicable Vercise System Direction for Use
- • At least 18 years old
- Key Exclusion Criteria:
- • Meets any contraindication in the Vercise System locally applicable Directions for Use
- • Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Tampa, Florida, United States
Boston, Massachusetts, United States
Cleveland, Ohio, United States
Nashville, Tennessee, United States
Chicago, Illinois, United States
Seattle, Washington, United States
Leuven, , Belgium
Jacksonville, Florida, United States
Albany, New York, United States
Winston Salem, North Carolina, United States
Boston, Massachusetts, United States
Düsseldorf, , Germany
Madrid, , Spain
Seoul, , Korea, Republic Of
Tel Hashomer, , Israel
Tel Aviv, , Israel
Freiburg, , Germany
Saint Louis, Missouri, United States
Würzburg, , Germany
London, , United Kingdom
Oxford, , United Kingdom
Créteil, , France
Newcastle, , United Kingdom
Miami, Florida, United States
Gent, , Belgium
London, , United Kingdom
Gainesville, Florida, United States
Barcelona, , Spain
Seoul, , Korea, Republic Of
Barcelona, , Spain
Hamburg, , Germany
Seoul, , Korea, Republic Of
Rome, , Italy
Glasgow, , United Kingdom
Jerusalem, , Israel
Houston, Texas, United States
Bristol, , United Kingdom
Liverpool, , United Kingdom
Paris, , France
Roeselare, , Belgium
Charlottesville, Virginia, United States
Tallahassee, Florida, United States
Québec, , Canada
Köln, , Germany
Lyon, , France
Innsbruck, , Austria
Udine, , Italy
Marseille, , France
Paris, Ile De France, France
Tel Aviv, , Israel
Aliso Viejo, California, United States
Aurora, Colorado, United States
Grand Junction, Colorado, United States
Boise, Idaho, United States
Indianapolis, Indiana, United States
Great Neck, New York, United States
San Antonio, Texas, United States
Sherman, Texas, United States
Spokane, Washington, United States
Halifax, , Canada
Rennes, , France
Berlin, , Germany
Hamm, , Germany
Kiel, , Germany
Mainz, , Germany
Marburg, , Germany
Oldenburg, , Germany
Pécs, , Hungary
Arcugnano, , Italy
Ferrara, , Italy
Mestre, , Italy
Milan, , Italy
Pavia, , Italy
Bydgoszcz, , Poland
Gdańsk, , Poland
Warsaw, , Poland
Madrid, , Spain
Murcia, , Spain
Oviedo, , Spain
London, , United Kingdom
Kirkland, Washington, United States
Williamsville, New York, United States
Ciudad Autonoma De Buenos Aires, , Argentina
Patients applied
Trial Officials
Natalie Bloom Lyons
Study Director
Boston Scientific Neuromodulation Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials